financetom
Business
financetom
/
Business
/
Why Is GameStop Stock Rising Monday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Is GameStop Stock Rising Monday?
Mar 23, 2026 10:46 AM

GameStop Corp ( GME ) shares are trading higher Monday. The move comes as the broader markets show strength. The Nasdaq rose 1.10%, while the S&P 500 gained 1.16%.

Investors are focusing on GameStop’s fourth-quarter earnings. The company reports these results on Tuesday. Analysts estimate earnings per share (EPS) of 31 cents. Revenue expectations sit at $1.47 billion.

GameStop ( GME ) carries significant momentum into this report. The company has beaten EPS estimates in six consecutive quarters.

In the third quarter, it reported an EPS of 24 cents. This surpassed the 18-cent analyst estimate.

Short Interest Data Shifts

Benzinga data shows short interest in GameStop ( GME ) decreased recently. It fell from 66.88 million to 65.62 million shares. This represents 16.04% of the company's float. It would take 13.98 days for short sellers to cover their positions.

Technical Analysis

GameStop ( GME ) is trading 3.8% below its 20-day simple moving average (SMA) and 1.7% above its 100-day SMA, a split that points to short-term pressure but a longer-term base that's still trying to hold.

Over the past 12 months, shares are down 10.33%, and the stock is positioned closer to its 52-week low than its high.

The RSI is at 37.70, which sits in neutral territory. Meanwhile, MACD is at -0.1190 and below its signal line at 0.0781.

Key Resistance: $24.00

Key Support: $22.00

GME Stock Price Activity: GameStop ( GME ) shares were up 1.71% at $22.96 at the time of publication on Monday, according to Benzinga Pro data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer seals $10 billion deal for Metsera as Novo Nordisk exits race
Pfizer seals $10 billion deal for Metsera as Novo Nordisk exits race
Nov 8, 2025
(Reuters) -Obesity drug developer Metsera has accepted Pfizer's $10 billion acquisition offer, ending a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, sparking a strategic fight for a coveted asset in the growing...
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance
Nov 7, 2025
Pfizer Inc. ( PFE ) secured a $10 billion deal to acquire obesity drug developer Metsera, Inc. ( MTSR ) , beating out Novo Nordisk ( NVO ) A/S after a heated bidding war that captivated Wall Street. Metsera Board Backs Deal Under the deal, Pfizer ( PFE ) will pay $86.25 per share, consisting of $65.60 in cash and...
BRIEF-Novo Nordisk Says Will Not Increase Its Proposal To Acquire Metsera, Inc.
BRIEF-Novo Nordisk Says Will Not Increase Its Proposal To Acquire Metsera, Inc.
Nov 8, 2025
Nov 8 (Reuters) - Novo Nordisk A/S: * NOVO NORDISK WILL NOT INCREASE ITS PROPOSAL TO ACQUIRE METSERA, INC. * NOVO NORDISK - WILL NOT INCREASE OFFER FOR METSERA * NOVO NORDISK: BELIEVE THAT STRUCTURE OF OUR POTENTIAL MERGER AGREEMENT IS COMPLIANT WITH ANTITRUST LAWS * NOVO NORDISK: CO WILL NOT INCREASE ITS OFFER TO ACQUIRE METSERA CONSISTENT WITH ITS...
Pfizer wins $10 billion bidding war for Metsera as Novo bows out
Pfizer wins $10 billion bidding war for Metsera as Novo bows out
Nov 8, 2025
(Reuters) -Obesity drug developer Metsera said on Friday that it had accepted Pfizer's $10 billion acquisition offer, ending a fierce bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Pfizer appeared to have locked up the acquisition in September before Novo jumped in last week with an unsolicited offer, sparking a strategic fight for a coveted...
Copyright 2023-2026 - www.financetom.com All Rights Reserved